Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra

Acta Pharmacologica Sinica
Ling-Yun LiZhong-Qin Liang

Abstract

To investigate the effects of bilobalide on the activation of NF-kappaB, and apoptosis of dopaminergic neurons induced by 6-hydroxydopamine (6-OHDA). A rat model of Parkinson's disease was produced with a unilateral infusion of 6-OHDA (8 mug) into the substantia nigra par compact. Bilobalide was administered 5, 10, and 20 mg/kg (ip) once a day for 7 d, starting 6 d prior to the 6- OHDA infusion. The rats were subjected to locomotor activity and rotational behavior testing 2 or 3 weeks after the 6-OHDA infusion. The expressions of tyrosine hydroxylase (TH) and NF-kappaB p65 were examined by immunofluorescence. The loss of dopaminergic neurons was detected by Nissl's staining. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was used to identify apoptosis. The behavioral changes due to 6-OHDA were significantly restored by bilobalide pretreatment. Bilobalide inhibited the 6-OHDA-induced loss of TH-positive neurons, decreased the activation of NF-kappaB, and protected dopaminergic neurons from apoptosis remarkably. NF-kappaB activation contributes to the 6-OHDA-induced loss of dopaminergic neurons, and the inhibition of the NF-kappaB pathway is likely to be involved in the neuroprotective effect of bilobalide.

References

Jan 1, 1986·Acta Neuropathologica·M OtaniG W Kreutzberg
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·S HunotE C Hirsch
Sep 25, 2001·Cellular and Molecular Neurobiology·A BarzilaiA Shirvan
May 15, 2002·European Journal of Pharmacology·Najat BouazizCarine Michiels
Jul 23, 2002·The Proceedings of the Nutrition Society·Michael GrundmanPatrick Delaney
Mar 22, 2003·Pharmacopsychiatry·D Eich-HöchliC B Eap
Sep 17, 2003·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Fei CaoE-tang Tong
Oct 3, 2003·Cellular and Molecular Life Sciences : CMLS·B Ahlemeyer, J Krieglstein
Nov 19, 2003·Journal of Alzheimer's Disease : JAD·Julie Vining Smith, Yuan Luo
May 14, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Victoria Tarabin, Markus Schwaninger
Nov 20, 2004·Phytotherapy Research : PTR·Süreyya Bïlmen SarikçioğluEvren Tercan
Dec 18, 2004·Fundamental & Clinical Pharmacology·D JanssensC Michiels
Mar 4, 2005·The International Journal of Biochemistry & Cell Biology·Shankar J Chinta, Julie K Andersen
Oct 4, 2006·Neuroscience·A MdzinarishviliJ Klein
Mar 16, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Flaubert TchantchouYuan Luo

❮ Previous
Next ❯

Citations

May 24, 2012·Oxidative Medicine and Cellular Longevity·Marlene Jimenez-Del-Rio, Carlos Velez-Pardo
Aug 29, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Norma Serrano-GarcíaCristina Trejo-Solís
Oct 31, 2009·Basic & Clinical Pharmacology & Toxicology·Isabel Cristina Avila-GomezMarlene Jimenez-Del-Rio
Oct 28, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Akanksha Mishra, Sairam Krishnamurthy
Jul 13, 2012·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Stefka Mincheva-Tasheva, Rosa M Soler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis